ClinicalTrials.gg
RecruitingNCT06649201Updated Sep 29, 2026

Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation

An observational study in Graft Vs Host Disease and Vulvovaginal Signs and Symptoms, sponsored by Case Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Case Comprehensive Cancer Center · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 454 studies in Graft vs Host Disease with a site in United States — 49 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Planned enrollment
27th of 43
40 · median 81
Started
2024
with 7 others
Observational
43 of 454
10 open now
Primary completion
2026-11
later than 14 of 66 live
Registered
432nd of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 27th largest by planned enrollment of the 43 observational ones that give a count, is one of 8 that started in 2024, is one of 43 observational ones, reaches primary completion later than 14 of the 66 other live ones, and was the 432nd registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

49 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to investigate the development of vulvovaginal graft-versus-host- disease (GVHD), an under-reported and under-recognized manifestation of chronic GVHD. This study aims to characterize the vaginal microbiome in participants undergoing allogeneic hematopoietic cell transplantation (HCT). The main questions it aims to answer are:

  • Is the vaginal microbiome altered during allogeneic HCT?
  • What changes may help researchers understand the development of vulvovaginal GVHD?

Participants will be asked to undergo an assessment of vulvovaginal symptoms through a vulvovaginal symptom questionnaire once pre-transplant, 6 months post-transplant, and twelve12 months post- transplant. Participants will also be asked to undergo a vaginal microbiome (collection of bacteria, fungi, and viruses that live on our bodies) evaluation through a vaginal exam performed by a gynecologist with collection of vaginal samples once pre-transplant and again six months post-treatment and twelve months post-transplant. If a participant develops symptoms of vulvovaginal GVHD at any point in time during the post-transplant follow up, the participant may partake in additional vaginal exams to diagnose GVHD at the time of symptom onset.

Read the detailed description

Recent advances in technologies including high throughput metagenomic 16S rRNA gene sequencing have revealed a larger, more complex picture of the bacterial diversity in the genital tract and unique microbial communities not previously recognized among the known vaginal flora categories. Little is known about how the vaginal microbiome protects the female genital tract or other roles it may have, including interacting with the microbiota of other body sites and subsequent inflammatory responses. Alteration of vaginal flora may play a part in the pathogenesis of diseases by modulating immunity or increasing the growth of pathogenic strains. Recent research has been conducted regarding changes in the vaginal microbiome during various infectious and inflammatory states such as bacterial vaginosis, pelvic inflammatory disease, sexually transmitted infectious, and pregnancy. However, the vaginal microbiome during allogeneic HCT and development of genital GVHD has yet to be examined. Thus, the role of the vaginal microbiome in the development of genital GVHD is a critical area of study.

03

Conditions studied

  • Graft Vs Host Disease
  • Vulvovaginal Signs and Symptoms

Browse trials for

Keywords

  • Allogeneic Hematopoietic Cell Transplantation
  • Vaginal Microbiome
  • GVHD
  • HCT
  • Vulvovaginal GVHD
  • Vulvovaginal graft-versus-host disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Female participants undergoing allogenic HCT will be recruited from the Blood and Marrow Transplant Program at the Cleveland Clinic.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants planning to undergo HCT for any disease indication, OR, female participants who have already received HCT and have developed vulvovaginal during their post-transplant follow-up period
  • All conditioning regimens (myeloablative or reduced intensity) will be included.
  • All donor sources (HLA matched/mismatched related, unrelated, umbilical cord, haploidentical) will be included.
  • All graft sources (bone marrow or peripheral blood stem cells) will be included.
  • All GVHD prophylaxis regimens will be included.
  • Aged 18-70.
  • English speaking and able to sign written .
  • Participants agree to a vaginal gynecologic exam.
  • Co-enrollment on other clinical trials will be allowed.

Exclusion criteria

Exclusion Criteria:

  • Participants who decline or unable to undergo vaginal gynecologic exam due to any discomfort or pain.
  • Any concurrent medical, psychiatric or other illness in which the provider believes the participants may not be able to comply with study assessments.
  • Participants with a current diagnosis of a sexually transmitted infection (STI) (Herpes Simplex Virus, Gonorrhea, Chlamydia, Trichomonas,) or a history of previously untreated STI which may incite inflammation that will impact the microbiome.
  • Participants with a history of lichen sclerosis, lichen planus, pre-transplant.
  • Participants with a history or current diagnosis of vaginal or vulvar .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Allogeneic HCT participants

    The cohort will be comprised of participants undergoing allogeneic HCT at the Cleveland Clinic.

    Other: Vulvovaginal Symptom Questionnaire · Diagnostic Test: Vaginal Microbiome Evaluation

Interventions

  • OtherVulvovaginal Symptom Questionnaire

    Participants will undergo assessment of vulvovaginal symptoms via the vulvovaginal questionnaire once pre-transplant, six months, and develop months post-transplant.

  • Diagnostic testVaginal Microbiome Evaluation

    A vaginal microbiome evaluation will be performed via vaginal exam by a gynecologist with collection of vaginal samples once pre-transplant, six months, and twelve months post-transplant.

06

What researchers measure

Primary outcomes

  1. Characterize the vaginal microbiome profile of female participants undergoing allogeneic HCT

    A primary objective of this study is to characterize the vaginal microbiome and in female participants undergoing allogeneic HCT.

    Time frame: Up to twelve months post-transplant

  2. Characterize the change in vaginal microbiome profile of female participants undergoing allogeneic HCT

    A primary objective of this study is to characterize the vaginal microbiome change in female participants undergoing allogeneic HCT.

    Time frame: Up to twelve months post-transplant

  3. Incidence of vulvovaginal GVHD

    A primary objective is to measure the incidence of vulvovaginal GVHD in this cohort.

    Time frame: Up to twelve months post-transplant

Secondary outcomes

  1. Characterize the differences in vaginal microbiome between participants who develop vulvovaginal GVHS versus those who do not

    The secondary objective is to investigate differences in vaginal microbiome between participants who develop vulvovaginal GVHD and those who do not.

    Time frame: Up to twelve months post-transplant

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Nov 2026, 23 months after the start.

Of 45 non-industry observational studies under Graft vs Host Disease, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 154. This study's planned 23 months is below that.

Counting every sponsor, half of 46 studies reached it within 60 months; a quarter within 37 and three quarters within 154.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2024
First posted
Oct 18, 2024
StartActual
Dec 19, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Feb 15, 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06649201
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Oct 18, 2024
Start date
Dec 19, 2024
Primary completion
Nov 2026 (estimated)
Completion
Feb 15, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Betty K Hamilton, MD
Contact
TaussigResearch@ccf.org
1-866-223-8100
Betty K Hamilton, MD
principal investigator · Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion